Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 2/2015

01.08.2015 | General Gynecology

Study results on the use of different therapies for the treatment of vaginitis in hospitalised pregnant women

verfasst von: Aleksandra Novakov Mikić, Sinisa Stojic

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

During pregnancy, many women experience vaginal infections due to a weakened immune system and changes in hormonal status. Treating these infections is of crucial importance, because women are at high risk for serious complications such as preterm birth and late miscarriage. For this reason, the present study was conducted to investigate the effectiveness of octenidine dihydrochloride/phenoxyethanol (OHP) in comparison to antimicrobial therapies in pregnant women in hospital suffering from different types of vaginitis.

Methods

A total of 1,000 patients were divided into 4 different groups according to their type of vaginal infection after smear analyses. Each group was again divided into two subgroups receiving treatment with OHP or antimicrobial therapies with neomycin/polymyxin B/nystatin, metronidazole or miconazole vaginal tablets.

Results

The most frequent causes of vaginitis were unspecific bacterial infections (42.4 %) and vaginal candidiasis (44.8 %). The average time needed to obtain negative results from smear analyses was significantly shorter when treated with OHP, both in patients with bacterial vaginosis (BV) or vaginal candidiasis (VC) compared to antimicrobial therapy (1.7 ± 0.8 vs. 2.3 ± 1.1 days; 2.3 ± 1.4 vs. 3.4 ± 1.6 days; both p < 0.001). Equally, the maximum number of days until negative results were detected was significantly lower with OHP compared to antimicrobial therapy (BV: 3 vs. 5 days; VC: 5 vs. 7 days).

Conclusions

OHP has a great effect in the treatment of vaginitis during pregnancy and thus should be an integral part of standard therapy regimens.
Literatur
1.
Zurück zum Zitat Linhares IM, Giraldo PC, Baracat EC (2010) New findings about vaginal bacterial flora. Rev Assoc Med Bras 56(3):370–374PubMedCrossRef Linhares IM, Giraldo PC, Baracat EC (2010) New findings about vaginal bacterial flora. Rev Assoc Med Bras 56(3):370–374PubMedCrossRef
2.
Zurück zum Zitat Antonio MA, Hawes SE, Hillier SL (1999) The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 180(6):1950–1956PubMedCrossRef Antonio MA, Hawes SE, Hillier SL (1999) The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 180(6):1950–1956PubMedCrossRef
3.
Zurück zum Zitat Yudin MH, Money DM (2008) Screening and management of bacterial vaginosis in pregnancy. J Obstet Gynaecol Can 30(8):702–716PubMed Yudin MH, Money DM (2008) Screening and management of bacterial vaginosis in pregnancy. J Obstet Gynaecol Can 30(8):702–716PubMed
4.
Zurück zum Zitat Aagaard-Tillery KM, Holmgren CM, Scott JR (2005) Gynecologic problems in women with autoimmune diseases. Handbook of systemic autoimmune diseases, vol 4. Elsevier, New York, pp 141–160 Aagaard-Tillery KM, Holmgren CM, Scott JR (2005) Gynecologic problems in women with autoimmune diseases. Handbook of systemic autoimmune diseases, vol 4. Elsevier, New York, pp 141–160
5.
Zurück zum Zitat Egan ME, Lipsky MS (2000) Diagnosis of vaginitis. Am Fam Physician 62(5):1095–1104PubMed Egan ME, Lipsky MS (2000) Diagnosis of vaginitis. Am Fam Physician 62(5):1095–1104PubMed
6.
Zurück zum Zitat Koban I, Bender CP, Assadian O, Kramer A, Hübner NO (2012) Clinical use of the antiseptic polihexanide for genital tract infections. Skin Pharmacol Physiol 25:298–304PubMedCrossRef Koban I, Bender CP, Assadian O, Kramer A, Hübner NO (2012) Clinical use of the antiseptic polihexanide for genital tract infections. Skin Pharmacol Physiol 25:298–304PubMedCrossRef
7.
Zurück zum Zitat Friese K, Neumann G, Siebert J (2003) Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis. Arch Gynecol Obstet 268(3):194–197PubMedCrossRef Friese K, Neumann G, Siebert J (2003) Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis. Arch Gynecol Obstet 268(3):194–197PubMedCrossRef
8.
Zurück zum Zitat Cullins VA, Dominguez L, Guberski T, Secor RM, Wysocki SJ (1999) Treating vaginitis. Nurse Pract 24(10):46 (9–50, 53–58 passim; quiz 64–65)PubMedCrossRef Cullins VA, Dominguez L, Guberski T, Secor RM, Wysocki SJ (1999) Treating vaginitis. Nurse Pract 24(10):46 (9–50, 53–58 passim; quiz 64–65)PubMedCrossRef
9.
Zurück zum Zitat Nygren P, Fu R, Freeman M, Bougatsos C, Klebanoff M, Guise JM (2008) Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the US preventive services task force. Ann Intern Med 148:220–233PubMedCrossRef Nygren P, Fu R, Freeman M, Bougatsos C, Klebanoff M, Guise JM (2008) Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the US preventive services task force. Ann Intern Med 148:220–233PubMedCrossRef
10.
Zurück zum Zitat Briese V, Neumann G, Walschläger J, May TW, Siebert J, Gerber B (2011) Efficacy and tolerability of a local acting antiseptic agent in the treatment of vaginal dysbiosis during pregnancy. Arch Gynecol Obstet 283(3):585–590PubMedCrossRef Briese V, Neumann G, Walschläger J, May TW, Siebert J, Gerber B (2011) Efficacy and tolerability of a local acting antiseptic agent in the treatment of vaginal dysbiosis during pregnancy. Arch Gynecol Obstet 283(3):585–590PubMedCrossRef
11.
Zurück zum Zitat Borges S, Silva J, Teixeira P (2014) The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet 289(3):479–489PubMedCrossRef Borges S, Silva J, Teixeira P (2014) The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet 289(3):479–489PubMedCrossRef
12.
Zurück zum Zitat Ries AJ (1997) Treatment of vaginal infections: candidiasis, bacterial vaginosis, and trichomoniasis. J Am Pharm Assoc 37(5):563–569 Ries AJ (1997) Treatment of vaginal infections: candidiasis, bacterial vaginosis, and trichomoniasis. J Am Pharm Assoc 37(5):563–569
13.
Zurück zum Zitat Friese K, Neumann G, Siebert J, Harke HP, Kirschner W (2000) Vergleich zweier lokaler Antiseptika in der klinischen Anwendung bei bakteriell bedingten Vaginalinfektionen. Geburtshilfe Frauenheilkd 60:308–313CrossRef Friese K, Neumann G, Siebert J, Harke HP, Kirschner W (2000) Vergleich zweier lokaler Antiseptika in der klinischen Anwendung bei bakteriell bedingten Vaginalinfektionen. Geburtshilfe Frauenheilkd 60:308–313CrossRef
14.
Zurück zum Zitat Swidsinski A, Loening-Baucke V, Swidsinski S, Verstraelen H (2014) Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report. Arch Gynecol Obstet. doi:10.1007/s00404-014-3484-1 PubMed Swidsinski A, Loening-Baucke V, Swidsinski S, Verstraelen H (2014) Polymicrobial Gardnerella biofilm resists repeated intravaginal antiseptic treatment in a subset of women with bacterial vaginosis: a preliminary report. Arch Gynecol Obstet. doi:10.​1007/​s00404-014-3484-1 PubMed
15.
Zurück zum Zitat Novakov Mikić A, Budakov D (2010) Comparison of local metronidazole and a local antiseptic in the treatment of bacterial vaginosis. Arch Gynecol Obstet 282(1):43–47PubMedCrossRef Novakov Mikić A, Budakov D (2010) Comparison of local metronidazole and a local antiseptic in the treatment of bacterial vaginosis. Arch Gynecol Obstet 282(1):43–47PubMedCrossRef
17.
18.
Zurück zum Zitat O’Hanlon DE, Moench TR, Cone RA (2013) Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One 8(11):e80074PubMedCentralPubMedCrossRef O’Hanlon DE, Moench TR, Cone RA (2013) Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One 8(11):e80074PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat McDonald HM, Brocklehurst P, Gordon A (2007) Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 24(1):CD000262 McDonald HM, Brocklehurst P, Gordon A (2007) Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 24(1):CD000262
20.
Zurück zum Zitat Cauci S, Driussi S, De Santo D, Penacchioni P, Iannicelli T, Lanzafame P, De Seta F, Quadrifoglio F, De Aloysio D, Guaschino S (2002) Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J Clin Microbiol 40(6):2147–2152PubMedCentralPubMedCrossRef Cauci S, Driussi S, De Santo D, Penacchioni P, Iannicelli T, Lanzafame P, De Seta F, Quadrifoglio F, De Aloysio D, Guaschino S (2002) Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J Clin Microbiol 40(6):2147–2152PubMedCentralPubMedCrossRef
Metadaten
Titel
Study results on the use of different therapies for the treatment of vaginitis in hospitalised pregnant women
verfasst von
Aleksandra Novakov Mikić
Sinisa Stojic
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 2/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3638-9

Weitere Artikel der Ausgabe 2/2015

Archives of Gynecology and Obstetrics 2/2015 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.